Submission Categories

Risk Factors, Risk Reduction & Tobacco Control This would include classic epidemiology, family history, gender differences, lung cancer in persons who have never smoked, exposure to radon, tobacco, and asbestos, cessation programs, chemoprevention, and efforts to reduce tobacco production, sales, and distribution. 
Tumor Biology – Preclinical Biology This would include in vitro basic science studies and cell lines.

Tumor Biology – Translational Biology This would include patient derived cells, animal models, and drug development studies.

Screening and Early Detection This would include low-dose computed tomography (LDCT) and radiology but also ongoing research into other methods and technologies to screen and detect thoracic cancers early.

Pulmonology and Staging This would include endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS), navigational bronchoscopy (NB), positron emission tomography (PET)-CT, mediastinoscopy, and staging system analyses.

Early-Stage Non-small Cell Lung Cancer This would include clinically related studies on localized/early-stage NSCLC, surgery, radiation therapy, neoadjuvant and adjuvant therapies, and immunotherapy and targeted therapies in this setting.

Pathology and Biomarkers This would include anatomic and molecular pathology, tissue and circulating biomarker studies, and clinical trial associated predictive biomarkers.

Local-Regional Non-small Cell Lung Cancer This would include clinically related studies on local-regional/locally advanced NSCLC (Stage III), surgery, radiation therapy, neoadjuvant and adjuvant therapies, immunotherapy and targeted therapies in this setting, and new multi-modality approaches.

Metastatic Non-small Cell Lung Cancer – Local Therapies This would include clinically relevant studies in metastatic/advanced NSCLC related to radiation therapy, surgery, and other ablative techniques.

Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including chemotherapy and nonclassical chemotherapy agents (ie ADCs), radiation oncology, new agents, new combinations, and new sequencing of drugs.

Metastatic Non-small Cell Lung Cancer – Immunotherapy This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including new agents, new combinations including radiation oncology, and new sequencing of drugs.

Metastatic Non-small Cell Lung Cancer – Targeted Therapy This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including new agents, new combinations including radiation oncology, and new sequencing of drugs.

Small Cell Lung Cancer and Neuroendocrine Tumors This would include clinically related studies on small cell lung cancer and neuroendocrine tumors. Strictly translational and basic science studies should go to tumor biology.

Mesothelioma, Thymoma, and Other Thoracic Tumors This would include clinically related studies on mesothelioma, thymoma, thymic carcinoma, and other thoracic tumors.

Multidisciplinary Care: Nursing, Allied Health and Palliative Care This would include nursing, allied health, palliative and supportive care, symptom management, decision-making, decision support techniques, ethics, quality of life, integrative care, rehabilitation, physiotherapy, and survivorship care.

Patient Advocacy This would include patient advocacy, patient survivorship, community outreach, patient-driven research, advocacy and patient foundations and organizations, patient reported outcomes, and lung cancer stigma.

Global Health, Health Services, and Health Economics This would include large real-world database studies across tumor types and stages, disparities identification and solutions, studies that examine the cost-effectiveness of therapies, diagnostics, or pathway implementation, programs that help improve the efficiency of health systems or patient management, and registry creation descriptions.

Education Awards

Education Awards are available for Early Career Professionals, Trainees, and Residents. These awards will consist of complimentary registration to the Conference, up to three nights’ accommodation, a fixed amount to cover travel expenses, and free membership to the IASLC for one year.

Eligibility for Education Award

Applicants with a professional degree, must be a fellow, student, trainee or a post-doctoral researcher within three years of initial faculty appointment (for example, the candidate must be appointed to faculty no later than October 2021)
Postdoctoral researchers from non-profit institutions (including academic and governmental institutions) are eligible to apply
Submitter and presenter of an abstract accepted for presentation at ACLC 2024

Supporting Documents Required for Application

Letter outlining why attending the Conference would benefit your career (max. 400 words)

Timeline

Application deadline: July 10,2024
Notifications of acceptance: August 5, 2024

Contact

For any education awards related questions, please contact meetings@iaslc.org.

Notification & Communication Policy

The IASLC will communicate the acceptance status of the submitted abstract with the individual listed under 'Contact Information' on the Abstract Submission Portal. It is the responsibility of this individual to communicate with alternate presenters, authors or individuals on their team.

Publication Schedule

Abstract titles will be listed on the website program one month prior to the start of the conference.

Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.

Confidentiality Policy

Authors who do not wish to have their abstracts published must notify the IASLC by email when submitting their final poster.

The authors of the abstract retain copyright, however IASLC reserves the right to sell and retain any revenue/income from selling the abstracts, presentation materials or recordings of the presentations.

Plagiarism Policy

Plagiarism encompasses all of the following:

Direct: intentionally submitting another person’s words or ideas verbatim as one’s own;

Self-plagiarism: submitting work that has been previously published or presented;

Mosaic plagiarism: stringing together portions of text from other sources;

Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated.

For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267/

Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of plagiarized content will be evaluated by IASLC staff and appropriate actions taken. Penalties for plagiarism may include: Rejection of abstract, and/or author(s) banned from making presentations at IASLC conferences.

For inquiries, please contact meetings@iaslc.org

No search results found

May

Abstract Submission Opens